News for Healthier Living

ASCO 2025 STUDY: New Standard of Care Emerges for Multiple Myeloma

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma. The randomized, multi-center ADVANCE clinical trial tests the effects of adding the targeted drug daratumumab to the standard three-part therapy regimen, called KRd (carfilzomib, lenalidomide and dexamethasone).

May 29, 2025


June 7 2025

June 6 2025

June 5 2025

June 4 2025

June 3 2025

June 2 2025

June 1 2025

May 31 2025

May 30 2025

May 29 2025

May 28 2025

May 27 2025

May 26 2025

May 25 2025

May 24 2025